Preoperative Serum FGF19 in the Prognosis of Biliary Atresia

Launched by CHILDREN'S HOSPITAL OF FUDAN UNIVERSITY · Apr 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a specific blood marker, called FGF19, can help doctors understand the likely outcomes for children with a condition known as biliary atresia. Biliary atresia is a serious liver condition that affects newborns, and knowing more about FGF19 levels before surgery could help predict how well a child may recover after treatment.

The trial is currently looking for participants who have been diagnosed with biliary atresia at the Children's Hospital of Fudan University. To be eligible, children must have records showing their health status one year after their surgery and their bilirubin levels (a substance in the blood) three months after the surgery. There are no specific exclusions, meaning that if a child meets the inclusion criteria, they may be able to participate. Families can expect to contribute blood samples and have their children's health monitored over time to help researchers gather important information that could improve care for future patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Samples diagnosed as biliary atresia in Children's Hospital of Fudan University
• • Samples with one-year follow-up records after surgery
• • Samples with a record of serum total bilirubin levels three months after surgery
• • Samples with preoperative serum left（volume \> 500ul)
• Exclusion Criteria:
• • None